Eli Lilly’s Mounjaro likely to become ‘leading therapy’ for obesity and type 2 diabetes

Eli Lilly’s blockbuster type 2 diabetes (T2B) drug Mounjaro is likely to become the dominant therapy in obesity and T2D, due to significant weight loss induced by it, says GlobalData.